Out-of-network with most major insurers, talk with our admissions team to get started.

CLINICAL MATRIX AND DATA VISUALIZATION

Comprehensive Clinical, Diagnostic & Functional Evaluation

Evaluating psychosis and schizophrenia requires an exhaustive, multi-domain framework spanning psychiatric differentiation, medical exclusion, neuro-motor examination, genetic risk stratification, formal thought analysis, functional capacity, and lifelong somatic surveillance.

Global Prevalence0.3% – 0.7%High global disease burden and morbidity

Life Expectancy Impact-20 YearsDriven by cardiovascular and somatic causes

NSS Prevalence50% – 65%Present in neuroleptic-naive patients

22q11.2DS Psychosis Risk25% – 30%Strongest single microdeletion risk

Section 1

Psychiatric Diagnostic Frameworks: DSM-5-TR vs ICD-11

Modern evaluation combines categorical diagnostic criteria with dimensional ratings to capture the deep phenotypic heterogeneity of schizophrenia. While DSM-5-TR mandates 6 months of continuous disturbance, ICD-11 focuses on a 1-month active threshold to minimize barriers to early intervention, placing explicit emphasis on passivity experiences and 6 clinical severity domains.

ICD-11 Dimensional Symptom Domain Ratings

Multidimensional severity profiling for personalized clinical tracking

ICD-11 Scale

Evaluating severity across these six specific domains acknowledges that cognitive impairment and mood symptoms profoundly dictate functional outcomes, even when categorical threshold is met.

Classification Criteria Comparative Analysis

Comparison of key diagnostic thresholds between systems

Duration ThresholdTemporal Boundary

DSM-5-TR:≥ 6 months continuous signs (includes prodromal/residual phases); ≥ 1 month active phase.

ICD-11:≥ 1 month active phase. Eliminates 6-month requirement to prevent delays in FEP care.

First-Rank / Core SymptomsPhenomenology

DSM-5-TR:≥ 1 of first 3 symptoms must be Delusions, Hallucinations, or Disorganized Speech.

ICD-11:Includes experiences of influence, passivity, or control (thought insertion/broadcasting) as core criteria.

Subtype StatusClassification Paradigm

Both DSM-5 and ICD-11 have officially eliminated classic subtypes (Paranoid, Disorganized, Catatonic) due to poor prognostic stability, replacing them with dimensional severity rating profiles.

Section 2

Psychosis Spectrum Differential Diagnosis

Differentiating schizophrenia from other psychotic and affective spectrum disorders hinges on two primary axes: total symptom duration and the temporal relationship between mood episodes and psychotic symptoms.

Psychotic vs Mood Episode Temporal Axis Comparison

Visualization of minimal duration requirements and mood concurrence across spectrum disorders

Schizoaffective Differentiator

Requires ≥ 2 weeks of psychotic symptoms in the complete absence of major mood episodes, while mood episodes occupy >50% of total illness duration.

Time-Bound Spectrum

Brief Psychotic Disorder (<1 month) and Schizophreniform Disorder (1–6 months) share identical positive symptoms but carry distinct prognostic timelines.

Delusional Disorder

Requires persistent non-bizarre/bizarre delusions ≥1 month without prominent hallucinations, severe speech disorganization, or severe functional collapse.

Section 3

First-Episode Psychosis (FEP) Medical Exclusion Workup

Secondary organic psychoses account for up to 1.5% of FEP in young adults and significantly higher rates in older populations. Comprehensive laboratory and neuroimaging panels are required to rule out reversible or life-threatening systemic and neurological etiologies.

FEP Primary vs Organic Secondary Etiology

Proportion of presentations in young adults

Routine Baseline MRI Yield:~6.0% Actionable

Number Needed to Assess (NNT):18 Patients

Identifies intracranial masses, demyelinating lesions (MS), or pronounced ventricular enlargement altering clinical care.

Tiered Laboratory & Neuro-Diagnostic Workup Matrix

Standard baseline versus targeted secondary diagnostic protocols

Tier 1

Universal Baseline Panel

CBC with Differential: Excludes active systemic infection, hematologic disease, baseline prior to Clozapine.
Comprehensive Metabolic Panel (CMP): Rules out uremia, hepatic encephalopathy, hyponatremia, and Addison's disease.
TSH & Thyroid Panel: Evaluates hyper/hypothyroidism, subacute thyroiditis, and Hashimoto's encephalopathy.
Urine/Blood Toxicology Screen: Differentiates methamphetamine, cannabis, or hallucinogen-induced psychosis.
Infectious Serology: HIV testing and Antitreponemal IgG (Neurosyphilis screening).

Tier 2

Targeted Secondary Panel

Autoimmune Encephalitis Panel: Anti-NMDA receptor antibodies (evaluated in atypical psychosis with rapid cognitive collapse).
ANA & Autoantibody Screen: Evaluates Neuropsychiatric Systemic Lupus Erythematosus (SLE).
Ceruloplasmin & Serum B12/MMA: Excludes Wilson's disease (copper accumulation) and subacute combined degeneration.
EEG & Structural Brain MRI: Evaluates temporal lobe epilepsy/seizures and intracranial structural pathology.

Section 4

Neurological Abnormalities: Catatonia & Neurological Soft Signs (NSS)

Evaluating motor disturbances is critical for safety and subtype management. Catatonia requires immediate cessation of antipsychotics and lorazepam challenge. Neurological Soft Signs (NSS) reflect non-localizing neurodevelopmental dysconnectivity across specific functional domains.

Catatonia (Bush-Francis Scale & Challenge)

BFCRS Protocol

The Bush-Francis Catatonia Rating Scale uses a 14-item screening (BFCSI) and a 23-item severity index. Presence of ≥2 screening items triggers a full assessment and immediate diagnostic challenge.

Waxy FlexibilityInitial slight candle-like resistance to passive positioning followed by compliance.

GegenhaltenAutomatic motor resistance proportional to the strength of examiner stimulus.

Mitgehen"Anglepoise Lamp Sign"Limb rises in response to light pressure despite explicit commands not to move.

Negativism / MutismMotiveless resistance to commands or severe verbal output restriction.

Lorazepam Diagnostic Challenge1 – 2 mg IV/IM

Positive Response: ≥ 50% reduction in total BFCRS score within 3 hours. Confirms catatonia diagnosis and dictates immediate treatment with high-dose benzodiazepines or ECT.

Neurological Soft Signs (NES) Domain Breakdown

Elevated scores in drug-naive FEP and healthy 1st-degree relatives serve as an endophenotype

3 NES Subdomains: (1) Motor Coordination (Tandem walk, rapid alternating movements), (2) Sensory Integration (Stereognosis, graphesthesia), (3) Complex Motor Acts Sequencing (Fist-edge-palm, rhythm tapping). Higher scores predict poorer pharmacological response.

Section 5

Genetics & Prodromal Risk

While genome-wide association studies show hundreds of common polygenic variants with tiny individual effects, 22q11.2 deletion syndrome represents a rare, highly penetrant structural variant accounting for ~1% of all schizophrenia cases.

22q11.2 Deletion Syndrome Profile

3.0 Mb Microdeletion on Chr 22: Imparts an extraordinary 25% to 30% lifetime risk of schizophrenia or related psychosis.

Key Clinical Phenotype Features:

Velopharyngeal insufficiency / cleft palate (hypernasal speech)
Congenital cardiac defects (Tetralogy of Fallot)
Dysmorphic facial features and hypocalcemia
High sensitivity to antipsychotic side effects

The "Second Hit" HypothesisAdditional CNVs or exonic duplications outside the 22q11.2 region modulate whether an individual ultimately converts to full psychotic illness.

22q11.2DS Age Trajectory: Cognitive Drop vs Psychosis Conversion

Longitudinal Phenotype Progression

*Note the characteristic quantitative drop in verbal IQ and executive function during early adolescence that precedes full-blown psychotic conversion between ages 18–25.

Section 6

Formal Thought Disorder & Functional Capacity Assessment

Formal Thought Disorder (FTD) is inferred through structured speech evaluation using Andreasen's TLC scale. Functional impairment is quantified separately from psychiatric symptoms using validated tools like SOFAS and PSP.

Scale for Thought, Language, & Communication (TLC)

Andreasen Framework: Positive vs Negative FTD

Positive Thought DisorderFiltering Deficit

• Derailment: Loose associations
• Tangentiality: Oblique/unrelated replies
• Incoherence: Severe "word salad"
• Neologisms: Coined idiosyncratic words
• Illogicality: Non-sequitur conclusions

Negative Thought DisorderProduction Deficit

• Poverty of Speech (Alogia): Minimal unelaborated responses
• Poverty of Content: Adequate length but empty of meaningful information
• Blocking: Sudden unexpected interruption of train of thought

Clinical Differentiator: Must distinguish psycholinguistic FTD from organic neurological aphasias (Wernicke's) or acute delirium during the diagnostic interview.

Personal & Social Performance (PSP) Scale

SOFAS Evolution

Evaluates 4 functional domains independently of psychiatric symptom severity

SOFAS Target Range: 0–100 Scale41–50: Serious Functional Impairment

Section 7

Somatic & Metabolic Surveillance Protocols

Second-Generation Antipsychotics (SGAs) carry severe metabolic risks including massive weight gain, dyslipidemia, and type 2 diabetes. The ADA/APA consensus guidelines mandate rigid longitudinal screening to intercept Metabolic Syndrome.

ADA / APA Consensus Metabolic Monitoring Schedule

Mandatory baseline and interval surveillance protocol for SGAs

Metabolic Parameter	Baseline	4 Weeks	8 Weeks	12 Weeks	Quarterly	Annually	5 Years
Personal / Family History	✓	—	—	—	—	✓	—
Weight & BMI	✓	✓	✓	✓	✓	—	—
Waist Circumference	✓	—	—	—	—	✓	—
Blood Pressure	✓	—	—	✓	—	✓	—
Fasting Plasma Glucose / HbA1c	✓	—	—	✓	—	✓	—
Fasting Lipid Profile	✓	—	—	✓	—	—	✓

Metabolic Syndrome Diagnostic Criteria

≥ 3 of 5 Criteria

Formal diagnostic parameters according to NCEP ATP III

1. Abdominal Obesity (Waist)> 40 in (Men) / > 35 in (Women)

2. Elevated Triglycerides≥ 150 mg/dL

3. Reduced HDL Cholesterol< 40 mg/dL (M) / < 50 mg/dL (W)

4. Elevated Blood Pressure≥ 130 / 85 mmHg

5. Fasting Glucose≥ 100 mg/dL

Note: Antipsychotic-naive patients possess intrinsic metabolic vulnerabilities (increased visceral adiposity and baseline insulin resistance) even prior to pharmacotherapy.

Real-World Monitoring Adherence Gap

Epidemiological gap between guidelines and real-world clinical practice

Systemic Care Deficit: Baseline lipid and glucose testing rates in routine clinical practice remain below 30%, representing a severe health-system level breakdown in preventative cardiometabolic care.

Section 8

Treatment Planning & Integrated Clinical Synthesis

Translating diagnostic, genetic, functional, and somatic findings into an evidence-based, person-centered recovery plan according to APA practice guidelines.

APA 1A Recommendation

Antipsychotic Pharmacotherapy

Core somatic intervention for acute phase management and relapse prevention. Selection guided by shared decision-making regarding side effect vulnerability.

First-Episode Focus

Coordinated Specialty Care (CSC)

Multidisciplinary team-based intervention combining low-dose medication, psychotherapy, case management, and supported employment/education.

Treatment Resistance

Clozapine Protocol

Uniquely indicated for treatment-resistant schizophrenia and persistent suicidality/aggression. Requires ANC monitoring for agranulocytosis risk.

Non-Adherence & Psychosocial

LAI & CBTp Integration

Long-Acting Injectable (LAI) antipsychotics for adherence challenges, paired with Cognitive Behavioral Therapy for psychosis (CBTp) and ACT services.